Pull to refresh
Logo
Daily Brief
Following
Why Sign Up
Mariano Barbacid

Mariano Barbacid

Director, Experimental Oncology Group at CNIO

Appears in 1 story

Stories

The race to drug KRAS in pancreatic cancer

New Capabilities

Leading triple therapy research toward clinical trials

For 40 years, the KRAS gene has been oncology's white whale—present in 90% of pancreatic cancers, yet resistant to every drug thrown at it. Scientists called it 'undruggable.' On January 28, 2026, Spanish researchers published results showing they had achieved what decades of effort could not: complete and lasting tumor elimination in mice using a triple-drug combination that blocks KRAS and two downstream pathways simultaneously.

Updated Jan 30